Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Alliance Foundation Trials, LLC.
Georg Pfeiler; Dominik Hlauschek; Erica L Mayer; Christine Deutschmann; Stephanie Kacerovsky-Strobl; Miguel Martin; Jane Lowe Meisel; Nicholas Zdenkowski; Sibylle Loibl; Marija Balic; Haeseong Park; Aleix Prat; Claudine Isaacs; Emilio Bajetta; Justin M Balko; Merixtell Bellet-Ezquerra; Judith Bliss; Harold Burstein; Fatima Cardoso; Hannes Fohler; Theodoros Foukakis; Karen A Gelmon; Matthew Goetz; Tufia C Haddad; Hiroji Iwata; Jacek Jassem; Soo-Chin Lee; Barbro Linderholm; Maartje Los; Eleftherios P Mamounas; Kathy D Miller; Patrick G Morris; Elisabetta Munzone; Einav Nili Gal-Yam; Alistair Ring; Lois Shepherd; Christian Singer; Christoph Thomssen; Ling-Ming Tseng; Pinuccia Valagussa; Eric P Winer; Antonio C Wolff; Gabriele Zoppoli; Jana Machacek-Link; Celine Schurmans; Xin Huang; Eric Gauthier; Christian Fesl; Amylou C Dueck; Angela DeMichele; Michael Gnant; PALLAS Groups and Investigators
Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ.